Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Discover 3 Promising ASX Penny Stocks Under A$400M Market Cap

In This Article:

The Australian share market is showing signs of an upswing, with ASX 200 futures indicating a modest gain as investors react to potential shifts in inflation data and interest rate expectations. Amid these broader market dynamics, penny stocks remain an intriguing area for investors seeking opportunities in smaller or newer companies. Despite their vintage name, penny stocks can offer surprising value when backed by strong financials, and this article explores three such promising candidates on the ASX that may hold long-term potential.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.78

A$143.12M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.58

A$67.99M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.98

A$247.08M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.50

A$310.07M

★★★★★☆

Helloworld Travel (ASX:HLO)

A$1.98

A$322.38M

★★★★★★

MaxiPARTS (ASX:MXI)

A$1.89

A$104.55M

★★★★★★

GTN (ASX:GTN)

A$0.53

A$104.08M

★★★★★★

IVE Group (ASX:IGL)

A$2.14

A$331.46M

★★★★☆☆

Servcorp (ASX:SRV)

A$4.98

A$491.43M

★★★★☆☆

Nickel Industries (ASX:NIC)

A$0.795

A$3.41B

★★★★★☆

Click here to see the full list of 1,031 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

4DMedical

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 4DMedical Limited is a medical technology company operating in the United States and Australia, with a market cap of A$240.57 million.

Operations: The company generates revenue from its Medical Technology R&D of Lung Function Analysis segment, amounting to A$3.75 million.

Market Cap: A$240.57M

4DMedical Limited, with a market cap of A$240.57 million, operates in the medical technology sector focusing on lung function analysis. Despite generating A$3.75 million in revenue from its R&D segment, it remains pre-revenue and unprofitable. The company has no debt and short-term assets exceed both its long-term (A$27.2M) and short-term liabilities (A$21.9M). However, it faces challenges with a negative return on equity (-50.73%) and less than one year of cash runway based on current free cash flow trends. Recent board changes include Director John Livingston transitioning to a Non-Executive Director role starting January 2025.

ASX:4DX Debt to Equity History and Analysis as at Jan 2025
ASX:4DX Debt to Equity History and Analysis as at Jan 2025

Lunnon Metals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Lunnon Metals Limited is an Australian company engaged in the exploration and development of nickel and gold, with a market cap of A$47.95 million.